To differentiate between benign and malignant tumor tissue using [¹⁸F]FDG. HCFA approved indications: Solitary pulmonary nodule, Staging of Lung Cancer, Lymphoma, Breast Cancer, Colorectal cancer, Head and neck Cancer, Melanoma, Thyroid cancer [elevated Tgb; negative I-131]
Quantitative dosimetry of readiolabeled monocloncal antibodies and small molecular weight ligands using Y-86, I-124.
Investigational tumor imaging with [¹⁸F] fluorocholine, [¹⁸F]fluorotyrosine

¹⁸F-FDG Lymphoma Study

PET with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) may play an important role in the evaluation and management of malignant lymphoma. FDG uptake is predictive of therapeutic response during the course of treatment. The adjacent images show advanced progression of the disease with focal nodules showing increased glucose metabolic uptake throughout the body.

¹¹C-5-Hydroxytryptophan (5-HTP)

5-HTP is a naturally-occurring amino acid and is also a precursor to production of the neurotransmitter serotonin. 5-HTP is preferentially taken up by carcinoid tumors of the liver that produce serotonin. The radiolabeled 11C analog of 5-HTP is shown to aggregate in tumor nodules of the liver as well as several metastatic sites throughout the body.

View Case Video

PET in Oncology